FDA Approves Therapy for Cerebral Folate Deficiency - Summary - MDSpire

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

  • By

  • Kathryn Wighton

  • March 10, 2026

  • 2 min

Share

Objective:

To announce the FDA's approval of Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency associated with FOLR1 variants.

Key Findings:
  • Wellcovorin is the first FDA-approved treatment for cerebral folate deficiency associated with FOLR1 variants.
  • The therapy may benefit individuals with developmental delays and autistic features.
  • Adverse reactions to leucovorin include pruritus, rash, dyspnea, and anaphylaxis.
Interpretation:

The approval signifies a major advancement for patients with a previously untreated rare genetic condition, showcasing the potential of real-world evidence in regulatory decisions.

Limitations:
  • The approval is specific to patients with confirmed FOLR1 variants.
  • Adverse reactions may limit the therapy's applicability in some patients.
Conclusion:

The FDA's approval of Wellcovorin represents a significant milestone in treating cerebral folate deficiency, providing hope for affected patients.

Original Source(s)

FDA Approves Therapy for Cerebral Folate Deficiency

  • by Kathryn Wighton

  • March 10, 2026

Related Content

Online Program Eases Pediatric Trauma Stress

Randomized trial evaluated therapist-assisted intervention among pediatric patients with persistent symptoms 1 month following trauma

Microstructural abnormalities in the ATR and VOF underlie tone awareness deficits in Chinese children with developmental dyslexia: a DTI study

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.